Related Experiment Videos
Neuroprotective effects of MK-801 against traumatic brain injury in immature rats
Ataç Sönmez1, Oya Sayın2, Seren Gülşen Gürgen3
1Department of Physiology, Faculty of Medicine, Dokuz Eylül University, 35340 Izmir, Turkey.
Insights
MK-801, an NMDA receptor antagonist, offers neuroprotection in young rats following traumatic brain injury (TBI). This treatment reduces hippocampal neuron loss and improves cognitive function and anxiety, highlighting its potential therapeutic role in pediatric TBI.
Area of Science:
- Neuroscience
- Pediatric Traumatology
- Pharmacology
Background:
- Traumatic brain injury (TBI) in pediatric populations presents significant long-term challenges.
- Hippocampal damage and cognitive deficits are common sequelae of TBI in immature brains.
- NMDA receptor antagonists are being investigated for neuroprotective effects.
Purpose of the Study:
- To evaluate the neuroprotective effects of MK-801, an NMDA receptor antagonist, on hippocampal damage and behavioral deficits in immature rats after TBI.
- To assess both short-term changes in hippocampal neurotrophic factors and receptor expression, and long-term cognitive outcomes.
Main Methods:
- 10-day-old rat pups were subjected to contusion injury followed by immediate intraperitoneal injection of MK-801 (1mg/kg).
- Histopathological (cresyl violet staining) and immunohistochemical analyses (BDNF, NGF, NMDAR) were performed on the hippocampus.
- Behavioral assessments, including elevated plus maze and novel object recognition tests, were conducted two months post-injury.
Main Results:
- MK-801 treatment significantly reduced trauma-induced hippocampal neuron loss in the CA1, CA3, and DG regions.
- The drug decreased the expression of BDNF, NGF, and NMDAR in the hippocampus.
- MK-801 administration ameliorated anxiety-like behavior and improved hippocampus-dependent memory in the injured rats.
Conclusions:
- Acute administration of MK-801 demonstrates a significant neuroprotective effect against TBI-induced hippocampal damage in immature rats.
- MK-801 mitigates both neuronal loss and associated cognitive impairments, suggesting its therapeutic potential for pediatric TBI.
Abstract:
Traumatic brain injury (TBI) is a major health problem in pediatric ages and also has major social, economic, and emotional outcomes, with diverse sequelae in many spheres of everyday life. We aimed to investigate the effect of MK-801, a competitive NMDA receptor antagonist, on hippocampal damage and behavioral deficits on 10-day-old rat pups subjected to contusion injury. The aims of the present study were to determine: (i) the short term effects of MK-801 on hippocampal BDNF, NGF and NMDA receptor immunoreactivity and neuron density in hippocampus (ii) long term effects of MK-801 on cognitive dysfunction following TBI in the immature rats. MK-801, was injected intraperitoneally at the doses of 1mg/kg of body weight immediately after induction of traumatic injury. Hippocampal damage was examined by cresyl violet staining, BDNF, NGF and NMDAR receptor immunohistochemistry on P10 day and behavioral alterations were evaluated using elevated plus maze and novel object recognition tests two months after the trauma. Histopathological and immunohistochemical evaluations showed that treatment with a single dose of 1mg/kg MK-801 (i.p.) significantly ameliorated the trauma induced hippocampal neuron loss and decreased BDNF, NGF and NMDAR expressions in CA1, CA3 and DG hippocampal brain regions. Additionally, treatment with MK-801 ameliorated anxiety and hippocampus dependent memory of animals subjected to trauma. These results show that acute treatment of MK-801 has a neuroprotective role against trauma induced hippocampal neuron loss and associated cognitive impairment in immature rats.